NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)

NCT05335031

CompletedN/A

Sponsor: Bristol-Myers Squibb

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Ozanimod

Countries: Germany

The purpose of this study is to collect real-world data and to gain insights about long-term usage of ozanimod (Zeposia ®), its effect on well-defined outcome parameters comprising participant-relevant outcomes, as well as quality of life, effectiveness, and incidence of adverse events.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Confirmed diagnosis of relapsing-remitting multiple sclerosis (RRMS)
* The decision upon treatment with ozanimod must have been made before enrollment and independently of this non-interventional observational study
* All data on ozanimod treatment are collected prospectively. The retrospective documentation of ozanimod therapy and enrollment of participants that are already on ozanimod therapy is not allowed

Exclusion Criteria:

* Special warnings, precautions and contraindications specified in the current version of the Summary of Product Characteristics (SmPC)
* Hypersensitivity to the active substance(s) or to any of the excipients of ozanimod as specified in the prescribing information must not be enrolled
* Participation in any other clinical studies

Other protocol-defined inclusion/exclusion criteria apply

Locations (1)

Dresden, Saxony, Germany